Evidence map›Paper›PMID 33758923›Full record

ArticleBriefings in bioinformatics2021

Machine learning on ligand-residue interaction profiles to significantly improve binding affinity prediction.

Beihong Ji, Xibing He, Jingchen Zhai, Yuzhao Zhang, Viet Hoang Man, Junmei Wang

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Physical chemistry chemical physics : PCCP · 2022
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Beihong JiDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Xibing HeDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-7431-7893
Jingchen ZhaiDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Yuzhao ZhangDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Viet Hoang ManDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Junmei WangDepartment of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-9607-8229

Funding

NIDA Center of Excellence OF Computational Drug Abuse Research (CDAR)P30DA035778 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAHAR, IVET, XIE, XIANG-QUN · 2014 to 2018
$5.4M
AMBER force field consortium: a coherent biomolecular simulation platformR01GM079383 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CIEPLAK, PIOTR, DUAN, YONG · 2007 to 2017
$4.7M
NIDA NIH HHS P30 DA035778NIGMS NIH HHS R01 GM079383
6 · The paper itself

Abstract

Structure-based virtual screenings (SBVSs) play an important role in drug discovery projects. However, it is still a challenge to accurately predict the binding affinity of an arbitrary molecule binds to a drug target and prioritize top ligands from an SBVS. In this study, we developed a novel method, using ligand-residue interaction profiles (IPs) to construct machine learning (ML)-based prediction models, to significantly improve the screening performance in SBVSs. Such a kind of the prediction model is called an IP scoring function (IP-SF). We systematically investigated how to improve the performance of IP-SFs from many perspectives, including the sampling methods before interaction energy calculation and different ML algorithms. Using six drug targets with each having hundreds of known ligands, we conducted a critical evaluation on the developed IP-SFs. The IP-SFs employing a gradient boosting decision tree (GBDT) algorithm in conjunction with the MIN + GB simulation protocol achieved the best overall performance. Its scoring power, ranking power and screening power significantly outperformed the Glide SF. First, compared with Glide, the average values of mean absolute error and root mean square error of GBDT/MIN + GB decreased about 38 and 36%, respectively. Second, the mean values of squared correlation coefficient and predictive index increased about 225 and 73%, respectively. Third, more encouragingly, the average value of the areas under the curve of receiver operating characteristic for six targets by GBDT, 0.87, is significantly better than that by Glide, which is only 0.71. Thus, we expected IP-SFs to have broad and promising applications in SBVSs.

Indexed as

Deep LearningAlgorithmsCrystallizationDatabases, ProteinDrug DiscoveryDrug Evaluation, PreclinicalHumansLigandsMolecular Docking SimulationMolecular StructureProtein BindingProtein KinasesReceptors, G-Protein-CoupledLigandsProtein KinasesReceptors, G-Protein-Coupledbinding affinity predictionmachine learning-based scoring function (ML-based SF)machine learning (ML)scoring function (SF)scoring powerstructure-based virtual screening (SBVS)

Identifiers

PMID33758923
PMCPMC8425425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.